ONCT vs. ITRM, QLI, FBRX, LUMO, BIOR, LPCN, UBX, LSTA, ACST, and TXMD
Should you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include Iterum Therapeutics (ITRM), Qilian International Holding Group (QLI), Forte Biosciences (FBRX), Lumos Pharma (LUMO), Biora Therapeutics (BIOR), Lipocine (LPCN), Unity Biotechnology (UBX), Lisata Therapeutics (LSTA), Acasti Pharma (ACST), and TherapeuticsMD (TXMD). These companies are all part of the "pharmaceutical preparations" industry.
Oncternal Therapeutics (NASDAQ:ONCT) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends, profitability and community ranking.
16.0% of Oncternal Therapeutics shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 8.0% of Oncternal Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Iterum Therapeutics received 108 more outperform votes than Oncternal Therapeutics when rated by MarketBeat users. Likewise, 62.10% of users gave Iterum Therapeutics an outperform vote while only 31.11% of users gave Oncternal Therapeutics an outperform vote.
Iterum Therapeutics has lower revenue, but higher earnings than Oncternal Therapeutics. Oncternal Therapeutics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Oncternal Therapeutics has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500.
Iterum Therapeutics has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -3,160.73%. Oncternal Therapeutics' return on equity of -97.25% beat Iterum Therapeutics' return on equity.
In the previous week, Oncternal Therapeutics had 8 more articles in the media than Iterum Therapeutics. MarketBeat recorded 11 mentions for Oncternal Therapeutics and 3 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 0.63 beat Oncternal Therapeutics' score of 0.38 indicating that Iterum Therapeutics is being referred to more favorably in the news media.
Oncternal Therapeutics currently has a consensus target price of $31.33, indicating a potential upside of 283.09%. Iterum Therapeutics has a consensus target price of $6.00, indicating a potential upside of 287.10%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Iterum Therapeutics is more favorable than Oncternal Therapeutics.
Summary
Iterum Therapeutics beats Oncternal Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Oncternal Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncternal Therapeutics Competitors List
Related Companies and Tools
